SUMMARY The relationship between plasma norepinephrine (NE), epinephrine (E) and dopamine-betahydroxylase activity (DBH) was studied in 90 cardiac patients (New York Heart Association [NYHA] classes I-IV), 85 healthy control subjects and 18 competitive skiers. The cardiac patients in NYHA classes III and IV had significantly higher NE (p < 0.001) and lower DBH (p < 0.001) levels than the controls, whereas the skiers had significantly lower NE (p < 0.001) and higher DBH (p < 0.05) levels than the controls. Seven cardiac patients in whom successful cardiac surgery was performed had decreased NE (p < 0.001) and increased DBH (p < 0.02), as well as significantly improved NYHA cardiac status (p < 0.001). These findings demonstrate an inverse relationship between NE and DBH in a population of athletes, normal subjects and cardiac patients; the same inverse relationship holds for these patients when sequential studies are done after a change in cardiac status.
DOPAMINE-BETA-HYDROXYLASE (DBH), which
catalyzes the conversion of dopamine to norepinephrinel (NE), is located in the chromaffin granules of the adrenal medulla2 and sympathetic nerve endings.' Animal studies have shown that during sympathetic nerve stimulation, liberation of NE from peripheral sympathetic nerve stores was accompanied by a proportional release of DBH4 from the sympathetic nerves through exocytosis.5 6 It was therefore proposed that both circulating NE and DBH activity could be used as indexes of sympathetic nerve activity.
Chidsey and Braunwald7 reported an increased level of circulating catecholamines in patients with congestive heart failure (CHF). Horowitz and Travis' reported that unlike NE, plasma DBH activity was low in patients with CHF, although NE was not measured in their study. The purpose of the present study was to determine the relationship of NE and DBH in a general population of patients with CHF both cross-sectionally and sequentially (in the same patient) following the dramatic changes after cardiac surgery. Both normal and supernormal (competitive skiers) subjects were studied as controls.
Materials and Methods

Patients
The characteristics of the tested population are shown in table 1. Patients with cardiac disease (59 men and 31 women) were 48 + 14 years old (mean + SD).
Fifty-two patients had valvular heart disease. 12 Abbreviations: HPLC = fluorometric catecholamine assay9 using high-performance liquid chromatography; REA = radioenzymatic assay;'3 NE = norepinephrine; E = epinephrine; n = number of subjects.
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Age
In 85 normal subjects, NE correlated positively with age (r = 0.367, p < 0.01), but DBH showed no correlation.
Long-term Stability
In 12 normal subjects over a mean period of 6.3 months, NE and DBH did not change significantly (NE from 150.9 + 105.1 to 133.0 ± 73.1 pg/ml, NS; DBH from 36.3 ± 12.5 to 38.3 ± 12.6 ,umol/l/min, NS). However, variation in percent change for NE was significantly greater than that for DBH (NE 23.0 ± 72.0%; DBH -6.3 ± 13.0%; p < 0.005, F test).
Discussion
Chidsey and Braunwald7 demonstrated increased levels of circulating catecholamines in patients with CHF. Plasma DBH activity was reported by Horowitz and Travis8 to be low in patients with CHF, although NE was not measured. However, simultaneous measurement of both in the same patient with CHF had never been done. The most important observation in this study was the significant and progressive decrease in DBH and the increase in NE as the heart disease progressed. This was observed in a cross-sectional study of a population of competitive skiers, healthy control subjects and cardiac subjects in various NYHA classes. The variability in each group can be explained by the genetic differences. Sequential studies of individual patients as the severity of the heart disease changed appreciably (valve replacement) show a consistent change in DBH overriding the genetic effect. 16 This may account for the variation in each age group. In the cardiac group, this factor, along with the subjective nature of the NYHA classification and the possible influence of the underlying heart disease, may explain some of the variation. However, the fact that DBH remains stable over a long period in a given normal subject (in whom no change in cardiac status is expected) suggests its clinical value.
The inverse relationship between DBH and NE in normal and cardiac subjects conflicts with the observation that NE and DBH are released proportionately4 after electrical stimulation in the guinea pig vas deferens. The mechanism for this discrepancy between experimental and clinical studies is not known. It has been reported that in patients with CHF increased plasma NE was accompanied by depletion of myocardial NE concentration and reduction of cardiac tyrosine hydroxylase activity. 17 However, an experiment in hamsters with heart failure"8 '9 showed no reduction in cardiac tyrosine hydroxylase activity. Carlsson and Lindqvist20 postulated that increased plasma NE is taken up by cardiac presynaptic sympathetic nerves and inhibits tyrosine hydroxylase activity by a neuronal negative feedback mechanism. There have been no studies of whether DBH depletion exists in the synaptic nerve endings of failing heart muscle. Oka et al. 2' reported that exogenous NE infusion decreased plasma DBH activity in healthy human subjects. If the reduction in DBH activity was a result of decreased DBH in presynaptic nerves, an increased plasma NE level may be responsible via the neuronal feedback mechanism.
Our study suggests that increased plasma NE coupled with decreased plasma DBH activity in patients with CHF may be related to the integrity of the peripheral sympathetic nervous system. Further study is needed to elucidate the actual mechanism. 
